Radu, L; Badea, A; Groot, G; Ellsworth, C; Young, C. What is the definition of an outbreak versus a cluster for COVID-19 in different clinical and community settings in Canada, the US, and the UK? 2020 Jul 27; Document no.: EOC071001 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 11 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc153
Ellsworth, C; Fox, L. What are the safety risks or disinfection concerns with the use of intubation boxes? 2020 Sep 2; Document no.: EOC090202-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 20 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc168
Asamoah, G; Groot, G; Badea, A; Ellsworth, C; Fox, L. What are the safety risks or disinfection concerns with the use of intubation boxes? 2020 Sep 8; Document no.: EOC090202 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 13 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc175
Miller, L; Howell-Spooner, B. Does data exist on the performance of triage or resource allocation frameworks for COVID-19 and other pandemics? 2020 Dec 8; Document no.: CC120401-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 20 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc219
Fick, F; Valiani, S; Miller, L; Howell-Spooner, B. Does data exist on the performance of triage or resource allocation frameworks for COVID-19 and other pandemics? 2020 Dec 17; Document no.: CC120401 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 91 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc225
Miller, L.; Mueller, M. What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? 2021 Jan 4; Document no.: EOC062201v2 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 46 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc232
Mueller, M; Howell-Spooner, B. How are other jurisdictions distributing COVID-19 vaccines in non-healthcare worker environments and what is the rationale for those distribution models? 2021 Jan 15; Document no.: PH011401-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 15 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc240
Badea, A; Groot, G; Mueller, M; Howell-Spooner, B. How are other jurisdictions distributing COVID-19 vaccines in non-healthcare worker environments and what is the rationale for those distribution models? 2021 Jan 19; Document no.: PH011401 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 17 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc246
Vanstone, J; Groot, G; Miller, L; Mueller, M. What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? 2021 Jan 22; Document no.: EOC062201v2 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc248
Vanstone, J; Groot, G; Miller, L; Mueller, M. What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? 2021 Jan 22; Document no.: EOC062201v2 RR Table. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST table) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc261
Miller, L; Young, C. What is the epidemiology of variants and what are the implications for healthcare? 2021 Feb 22; Document no.: EOC022201-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 28 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc265
Asamoah, G; Badea, A; Hernandez-Ronquillo, L; Lee, S; Shumilak, G; Reeder, B; Groot, G; Muhajarine, N; Miller, L; Howell-Spooner, B. What is the epidemiology of variants and what are the implications for healthcare? 2021 Dec 20. Document no.: EOC031801v019 RR Table. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. (CEST table). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc292
Ellsworth, C; Young, C. What is the definition of an outbreak versus a cluster for COVID-19 in different clinical and community settings in Canada, the US, and the UK? 2020 Jul 10; Document no.: EOC071001-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 9 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc133
Dalidowicz, M; Young, C. What is the degree of COVID-19 transmission through the administration of nebulizer medication either in clinical practice or in animal experiments? 2020 Apr 1; Document no.: EOC040101-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 12 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc10
Howell-Spooner, B. How do we decrease surge demand in acute care? 2020 Mar 30; Document no.: EOC033003-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 10 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc16
Duncan, V. Is the IgM or IgG immune response protective? 2020 Apr 8; Document no.: LAB040803-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 13 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc38
Duncan, V. At what time in the disease timeline of COVID-19 do antibodies develop? 2020 Apr 14; Document no.: LAB041402-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 42 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc39
Vanstone, J; Reeder, B; Duncan, V. At what time in the disease timeline of COVID-19 do antibodies develop? 2020 Apr 15; Document no.: LAB041402 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 4 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc43
Wang, H; Reeder, B; Duncan, V; Is the IgM or IgG immune response protective? 2020 Apr 11; Document no.: LAB040803 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 6 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc48
Young, C; Dalidowicz, M; Mueller, M. What is the period of communicability of symptomatic SARS-CoV-2? 2020 Apr 25; Document no.: INF042401-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 35 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc56
